Summary of project PR002527
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002527. The data can be accessed directly via it's Project DOI: 10.21228/M80R9W This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Project ID: | PR002527 |
| Project DOI: | doi: 10.21228/M80R9W |
| Project Title: | Serum Metabolites at Defined Stages of Liver Disease |
| Project Summary: | The present dataset comprises a total of 978 compounds of known identity (named biochemicals). Following log transformation and imputation of missing values, if any, with the minimum observed value for each compound, ANOVA contrasts were used to identify biochemicals that differed significantly between experimental groups. A summary of the numbers of biochemicals that achieved statistical significance (p≤0.05), as well as those approaching significance (0.05<p<0.10), is shown below. Analysis by two-way ANOVA identified biochemicals exhibiting significant interaction and main effects for experimental parameters of time and treatment. An estimate of the false discovery rate (q-value) is calculated to take into account the multiple comparisons that normally occur in metabolomic-based studies. For example, when analyzing 200 compounds, we would expect to see about 10 compounds meeting the p≤0.05 cut-off by random chance. The q-value describes the false discovery rate; a low q-value (q<0.10) is an indication of high confidence in a result. While a higher q-value indicates diminished confidence, it does not necessarily rule out the significance of a result. Other lines of evidence may be taken into consideration when determining whether a result merits further scrutiny. Such evidence may include a) significance in another dimension of the study, b) inclusion in a common pathway with a highly significant compound, or c) residing in a similar functional biochemical family with other significant compounds. Refer to the Appendix for general definitions and further descriptions of false discovery rate and other statistical tests used at Metabolon. |
| Institute: | University of Texas Health Science Center at Houston |
| Department: | IMM |
| Laboratory: | Mahan Lab |
| Last Name: | Fekry |
| First Name: | Baharan |
| Address: | The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), 1825 Pressler St, Houston TX 77030. USA. |
| Email: | Baharan.Fekry@uth.tmc.edu |
| Phone: | 8434693199 |
Summary of all studies in project PR002527
| Study ID | Study Title | Species | Institute | Analysis(* : Contains Untargted data) | Release Date | Version | Samples | Download(* : Contains raw data) |
|---|---|---|---|---|---|---|---|---|
| ST004035 | Serum Metabolites at Defined Stages of Liver Disease | Mus musculus | University of Texas Health Science Center at Houston | MS | 2025-07-15 | 1 | 40 | Uploaded data (6.1M) |
